Sequenom is dedicated to improving the diagnosis of medical conditions and diseases by developing novel nucleic acid based in vitro diagnostic tests. The company is currently focused on developing prenatal and retinal care diagnostics.

Sequenom has exclusive rights to intellectual property for noninvasive prenatal testing using circulating cell-free fetal nucleic acids. Read More...

In the area of retinal care diagnostics, the company has exclusive worldwide licenses to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD). Read More...